Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 65,761 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $149.11, for a total value of $9,805,622.71. Following the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $78,055,804.58. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $152.01 on Thursday. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 147.58 and a beta of 1.78. Protagonist Therapeutics, Inc. has a 1 year low of $54.18 and a 1 year high of $152.70. The stock’s fifty day moving average is $127.64 and its two-hundred day moving average is $106.78.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The business had revenue of $213.47 million during the quarter, compared to analyst estimates of $212.03 million. The company’s quarterly revenue was up 3746.8% compared to the same quarter last year. As a group, analysts predict that Protagonist Therapeutics, Inc. will post 4.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Protagonist Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTGX. Farther Finance Advisors LLC boosted its stake in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics in the 4th quarter worth $27,000. Keating Financial Advisory Services Inc. bought a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth $30,000. Allworth Financial LP acquired a new stake in shares of Protagonist Therapeutics in the second quarter valued at $31,000. Finally, Quantbot Technologies LP bought a new position in Protagonist Therapeutics during the second quarter valued at about $42,000. Institutional investors own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PTGX. The Goldman Sachs Group raised Protagonist Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $110.00 to $186.00 in a report on Monday. Barclays increased their price objective on Protagonist Therapeutics from $151.00 to $153.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Wall Street Zen cut Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research lowered Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 7th. Finally, Citigroup lifted their price objective on shares of Protagonist Therapeutics from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.86.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: An analyst article maintained a “Strong Buy” view, citing FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, attractive partnership economics and additional pipeline opportunities. Investors are also watching the FDA’s expected August 2026 Priority Review decision for rusfertide, which could lead to significant milestones and royalty payments from Takeda. The company plans to begin a Phase 2b study of oral IL-17 antagonist PN-881 in the first quarter of 2027. Protagonist Therapeutics: Strong Buy—ICOTYDE FDA Approval and PN-881 Advancement
• Positive Sentiment: A psoriasis-focused stock roundup included PTGX among companies offering exposure to approved therapies, late-stage candidates and earlier-stage psoriasis programs. This reinforces investor interest in Protagonist’s inflammatory-disease pipeline, although the article does not provide a new company-specific catalyst. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear anomalous, they provide little meaningful indication of near-term short-covering or bearish pressure.
• Negative Sentiment: CEO Dinesh V. Patel sold a combined 100,000 shares for approximately $14.9 million in transactions dated August 10 and 11. The sales reduced his reported ownership, which can pressure sentiment; however, both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, making them less indicative of a fresh change in management’s outlook. SEC insider transaction filing

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.